Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.30
SPPI's Cash to Debt is ranked lower than
76% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. SPPI: 1.30 )
Ranked among companies with meaningful Cash to Debt only.
SPPI' s 10-Year Cash to Debt Range
Min: 0.2  Med: 16.00 Max: 17918
Current: 1.3
0.2
17918
Equity to Asset 0.49
SPPI's Equity to Asset is ranked lower than
70% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SPPI: 0.49 )
Ranked among companies with meaningful Equity to Asset only.
SPPI' s 10-Year Equity to Asset Range
Min: 0.2  Med: 0.61 Max: 0.95
Current: 0.49
0.2
0.95
F-Score: 5
Z-Score: 0.65
M-Score: -3.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -15.55
SPPI's Operating margin (%) is ranked higher than
62% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. SPPI: -15.55 )
Ranked among companies with meaningful Operating margin (%) only.
SPPI' s 10-Year Operating margin (%) Range
Min: -68658.54  Med: -456.43 Max: 30.17
Current: -15.55
-68658.54
30.17
Net-margin (%) -23.55
SPPI's Net-margin (%) is ranked higher than
59% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. SPPI: -23.55 )
Ranked among companies with meaningful Net-margin (%) only.
SPPI' s 10-Year Net-margin (%) Range
Min: -67890.24  Med: -410.44 Max: 35.19
Current: -23.55
-67890.24
35.19
ROE (%) -17.14
SPPI's ROE (%) is ranked higher than
59% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. SPPI: -17.14 )
Ranked among companies with meaningful ROE (%) only.
SPPI' s 10-Year ROE (%) Range
Min: -888.98  Med: -44.77 Max: 39.19
Current: -17.14
-888.98
39.19
ROA (%) -9.02
SPPI's ROA (%) is ranked higher than
65% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. SPPI: -9.02 )
Ranked among companies with meaningful ROA (%) only.
SPPI' s 10-Year ROA (%) Range
Min: -321.68  Med: -37.73 Max: 23.98
Current: -9.02
-321.68
23.98
ROC (Joel Greenblatt) (%) -494.27
SPPI's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. SPPI: -494.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5547.35  Med: -1535.63 Max: 3089.46
Current: -494.27
-5547.35
3089.46
Revenue Growth (3Y)(%) -4.60
SPPI's Revenue Growth (3Y)(%) is ranked lower than
54% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SPPI: -4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -3.00 Max: 211.9
Current: -4.6
0
211.9
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SPPI Guru Trades in Q2 2014

Jim Simons 185,917 sh (+8.53%)
» More
Q3 2014

SPPI Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

SPPI Guru Trades in Q4 2014

Jim Simons 248,000 sh (New)
» More
Q1 2015

SPPI Guru Trades in Q1 2015

Paul Tudor Jones 38,000 sh (New)
Jim Simons 1,391,217 sh (+460.97%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 20.70
SPPI's Forward P/E is ranked higher than
59% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. SPPI: 20.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.01
SPPI's P/B is ranked higher than
81% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. SPPI: 2.01 )
Ranked among companies with meaningful P/B only.
SPPI' s 10-Year P/B Range
Min: 0.63  Med: 2.22 Max: 5.23
Current: 2.01
0.63
5.23
P/S 2.42
SPPI's P/S is ranked higher than
85% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. SPPI: 2.42 )
Ranked among companies with meaningful P/S only.
SPPI' s 10-Year P/S Range
Min: 1.07  Med: 4.29 Max: 650
Current: 2.42
1.07
650
PFCF 14.42
SPPI's PFCF is ranked higher than
84% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. SPPI: 14.42 )
Ranked among companies with meaningful PFCF only.
SPPI' s 10-Year PFCF Range
Min: 6.7  Med: 14.40 Max: 427
Current: 14.42
6.7
427
POCF 14.42
SPPI's POCF is ranked higher than
82% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. SPPI: 14.42 )
Ranked among companies with meaningful POCF only.
SPPI' s 10-Year POCF Range
Min: 6.6  Med: 12.16 Max: 34.03
Current: 14.42
6.6
34.03
Current Ratio 1.97
SPPI's Current Ratio is ranked lower than
74% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. SPPI: 1.97 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s 10-Year Current Ratio Range
Min: 0.56  Med: 2.84 Max: 16.82
Current: 1.97
0.56
16.82
Quick Ratio 1.88
SPPI's Quick Ratio is ranked lower than
70% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. SPPI: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s 10-Year Quick Ratio Range
Min: 0.56  Med: 2.70 Max: 16.8
Current: 1.88
0.56
16.8
Days Inventory 136.46
SPPI's Days Inventory is ranked lower than
57% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. SPPI: 136.46 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s 10-Year Days Inventory Range
Min: 78.11  Med: 121.61 Max: 332.36
Current: 136.46
78.11
332.36
Days Sales Outstanding 135.41
SPPI's Days Sales Outstanding is ranked lower than
83% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. SPPI: 135.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s 10-Year Days Sales Outstanding Range
Min: 9.09  Med: 120.06 Max: 4219.76
Current: 135.41
9.09
4219.76

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.36
SPPI's Price/Projected FCF is ranked higher than
87% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. SPPI: 1.36 )
Ranked among companies with meaningful Price/Projected FCF only.
SPPI' s 10-Year Price/Projected FCF Range
Min: 1.19  Med: 1.96 Max: 9.32
Current: 1.36
1.19
9.32
Price/Median PS Value 0.56
SPPI's Price/Median PS Value is ranked higher than
83% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. SPPI: 0.56 )
Ranked among companies with meaningful Price/Median PS Value only.
SPPI' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 3.52 Max: 2462.5
Current: 0.56
0.14
2462.5
Earnings Yield (Greenblatt) (%) -6.80
SPPI's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SPPI: -6.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPPI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.6  Med: 11.65 Max: 2183.8
Current: -6.8
1.6
2183.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
http://seekingalpha. Aug 14 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference and Webcast Jul 30 2015
Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference and Webcast Jul 30 2015
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 02 2015
Edited Transcript of SPPI presentation 3-Jun-15 2:00pm GMT Jun 27 2015
Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as a Rapid Communication... Jun 24 2015
Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as a Rapid Communication... Jun 24 2015
Edited Transcript of SPPI earnings conference call or presentation 7-May-15 8:30pm GMT Jun 12 2015
Armistice Capital Raising the Stakes Against Spectrum Pharmaceuticals, Inc. (SPPI) In Its First... Jun 04 2015
Wall Street expects these health-care stocks to rise up to 55% May 29 2015
Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of... May 29 2015
Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of... May 29 2015
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference... May 28 2015
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference... May 28 2015
13Ds: Perry Ellis Irks Legion, Spectrum Pharma Baffles Armistice May 15 2015
SPECTRUM PHARMACEUTICALS INC Financials May 15 2015
Spectrum Pharmaceuticals Commits to Review Shareholder Proposal May 14 2015
Spectrum Pharmaceuticals Commits to Review Shareholder Proposal May 14 2015
Spectrum Pharmaceuticals (SPPI) in Focus: Stock Up 10.1% - Tale of the Tape May 13 2015
Spectrum Pharmaceuticals Up 10% On Activist's Letter May 12 2015
10-Q for Spectrum Pharmaceuticals, Inc. May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK